The FDA accepts under Priority Review Gilead Sciences (NASDAQ:GILD) unit Kite Pharma’s marketing application for CAR T therapy KTE-X19 for the treatment of adults with relapsed/refractory mantle cell lymphoma, a rare and aggressive type of non-Hodgkin lymphoma (NHL).
The agency’s action date is August 10.
https://seekingalpha.com/news/3540022-fda-accepts-kite-application-for-car-t-for-aggressive-type-of-nhl
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.